September 21, 2021
This Weekly's Hot Topics
  • TOMORROW, September 22, live webinar on Prostate Cancer Awareness. MOASC News/MOASC Programs

  • September 23, 2021, webinar on challenges of the most pressing issues facing medical practices. California News

  • $25.5 billion in COVID-19 relief funds to help health care providers hit by the pandemic. National News

  • Some 340B hospitals charging insurers an average of 3.8 times more than acquisition costs for oncology drugs. National News
MOASC Programs - Save the Dates - All Times are Pacific
September 22, 5:30-6:30pm PDT, MOASC will host a live webinar on Prostate Cancer Awareness, with panel discussions on initial treatment of Metastatic Castration Sensitive Prostate Cancer/Increase in newly diagnosed; current thoughts on radiation for primary tumor in Metastatic Disease and new treatments in Castration Resistance Disease in conjunction with genomic testing/PARP inhibitors presented by: Ashkan Lashkari, M.D., MOASC President; Christopher DeSantis, California Urological Association; John Lam, M.D., Kaiser Permanente, Los Angeles; Nataliya Mar, M.D., Assistant Professor, UCI and Steven N. Seyedin, M.D., Assistant Clinical Professor, UCI. This event is complementary but registration is required. 
September 25, 2021, Cedars Sinai’s 2021 Annual Seminar for GI Nurses and Associates directs content to GI Nurses and Interdisciplinary Professionals.
MOASC Members are invited to two upcoming webinars through Targeted Oncology.
On Thursday, September 30th, 7:00-8:30pm PDT, a virtual roundtable meeting oncologists treating PARP Inhibition as Primary Maintenance Therapy for Advanced Ovarian Cancer.
On Wednesday, October 6th, 7:00-8:30pm PDT, a virtual roundtable meeting is intended for oncologists treating Myeloproliferative neoplasms: Myelofibrosis and Polycythemia Vera.
October 2, 2021, 8am-12pm SAVE THE DATE for MOASC’s Spotlight On Oncology. MOASC Board member, Jason Zell, MD will moderate discussions on: Melanoma presented by Omid Hamid, MD; Genitourinary Cancer presented by Nataliya Mar, MD; Upper Gastrointestinal Cancer presented by Jennifer Valerin, MD; Lower Gastrointestinal Cancer presented by May T. Cho, MD; Lung Cancer presented by Misako Nagasaka, MD, and Breast Cancer presented by Ritesh Parajuli, M.D. 
October 29-30, the University of California San Diego invites you to their inaugural Delivering Discoveries: Updates in Oncology CME conference. The diagnosis and management of cancer patients is increasingly complex and requires multidisciplinary management. This 1.5 day event will address all aspects of cancer from basic science research, advances in clinical care, to community-based approaches that optimize prevention and interception. 
November 4 and November 10, SAVE THE DATE for MOASC’S Annual Practice Management Series! The virtual Educational Series will be presented in two tracks.
Track one – Oncology Administration November 4 from 11:45am – 3:15pm
Topics include: How to deal with Employee Fatigue, Time Management and Process Automation for Practices.
Track two – Oncology Billing November 10 from 11:45am – 3:15pm
Topics include: 2022 Billing updates, Overview of Medicare Regulations, Positioning Your Physician Organization for Financial Success and How to Increase Revenue.
There will be opportunity for attendees to spend time Networking in the Zoom Room with our gracious Sponsors. Thank you, AstraZeneca, BeiGene, Bristol Myers Squibb, Grail, Inc., Oncopeptides, Pfizer Oncology, Takeda Oncology, AbbVie, Astellas, Daiichi Sakyo, Inc., Incyte, Johnson and Johnson, Merck, Novartis, ADC Therapeutics, Agios Pharmaceuticals, Exact Sciences, Foundation Medicine, Gilead, G1 Therapeutics, Guardant Health, Kite Pharma, Lilly Oncology, Morphosys, Inc., Myovant Sciences, Pharmacyclics, Sanofi-Genzyme, Seagen, Stemline Therapeutics, Walgreens Coherus Biosciences, Rigel Pharmaceuticals, VerdePharm Health.
California News
California oncology groups and supporters have succeeded in moving SB 310 (Rubio) through the legislature. The bill ensures patients’ access to needed anti-cancer medications. The bill will create a program that allows oncologists to accept unused, unneeded, medication from their patients and redistribute that medication to other patients in need. The bill passed through the Legislature without opposition and is now on its way to the Governor. The Governor has until October 10 to sign or veto the bill.
September 23, 2021, CMA is hosting a webinar to provide physician practices the information they need to avoid billing challenges to two of the most pressing issues facing medical practices at this stage of the COVID-19 pandemic: Telehealth and COVID-19 vaccine administration. Speakers will provide a brief overview of the current federal and state telehealth flexibilities in place as a result of the COVID-19 pandemic.
The California Dialogue On Cancer is taking on new initiatives. The new Health Equity Workgroup is in the beginning stages of planning for the Sexual Orientation and Gender Identity Plus (SOGI+) Data Project. There is also the American Cancer Society's Get Screened Campaign that CDOC is helping to tailor for the diverse population of our state. Learn more about these initiatives including CDOC's other workgroup activities and progress on cancer plan implementation projects at the next CDOC All Members Meeting on September 30th at noon.
Medicare News
Noridian Programs
September 22 – 23, Noridian invites you to experience their Virtual Fall Symposium. Meet and engage with your provider education Part A and B team members, where you may pick and choose which sessions you're interested in attending. Each session will be 55 minutes long and you will be required to sign up for each session provided.
September 23, Preventive Services: Flu and PPV Vaccines
This webinar will review the coverage, coding and billing guidelines under Medicare Part B for Influenza and Pneumococcal Pneumonia Virus vaccinations.
Quarterly Medicare Updates - A/B Webinar - October 5, 2021
This event includes: CMS and Noridian Updates, October 2021 Quarterly Provider Updates, Change Requests (CR), Recurring Updates, Special Editions (SE), and Resources 
Quarterly Medicare Updates - A/B - After Hours Webinar - October 14, 2021
This event includes: CMS and Noridian Updates, October 2021 Quarterly Provider Updates, Change Requests (CR), Recurring Updates, Special Editions (SE), and Resources.
CMS News
Help CMS Improve Provider Resources by taking this confidential Medicare survey. asking about information and resources you use to understand the Medicare program and/or help you bill correctly. AIHC is an educational partner with CMS and asks you to take a few minutes to complete an important Medicare billing survey from CMS. The survey is part of a study CMS is conducting to help improve your experience with resources about the Medicare program and correct billing. Responses are confidential, and the survey should take about 10 minutes to complete. Please participate by sharing your thoughts.
October 5, 2021, 10am PDT, join Bobbi Buell for a free webinar on the Proposed Outpatient Prospective Payment System Rule which is slated to start January 1, 2022.
National News
HHS will distribute $25.5 billion in COVID-19 relief funds from the American Rescue Plan to help hospitals and other health care providers hit by the pandemic, following pressure from lawmakers and medical groups. About $17 billion will be set aside for applicants who can demonstrate pandemic-related revenue losses, while $8.5 billion will go to those in rural areas.
A report from the Community Oncology Alliance found that some hospitals that take part in the 340B discount program are charging insurers 3.8 times on average more than the acquisition costs for oncology drugs. "In short, to the extent 340B institutions fulfill their mission of providing lower cost care, we are not seeing it reflected in their drug prices," according to the researchers.
Acting FDA Commissioner Janet Woodcock sent a letter urging the US Patent and Trademark Office to act on anticompetitive patent practices in the pharmaceutical industry. Woodcock raised concerns about patents for small product changes and the practice of moving patients to new formulations, citing a study that found existing drugs accounted for 78% of new drug patents listed from 2005 to 2015.
Affiliate Association News
UC Davis is conducting a Medical Oncologist Survey. If you are a medical oncologist, we'd like to invite you to participate in a survey about genetic counseling and for the chance to win an iPad. Please contact with any questions.
ANCO's 2021 Professional Education Meeting is taking place virtually on October 27th. Registration opens on September 24th.
ANCO's Hematologic Malignancies Updates (part III of III), will be November 6, 2021- Hyatt Regency San Francisco Embarcadero. The faculty will present the latest research on treatment modalities for hematologic malignancies—leukemias, lymphomas, and myeloma—along with case studies for these diagnoses. Registration deadline is Thursday, November 4th.
Four seats on the ANCO Board of Directors are up for election in 2021. ANCO seeks nominations for candidates to stand for election to these seats. This year's election will be conducted via election runner online in December. Candidates with the top four vote totals will serve for three years (i.e., from 2022-2024, inclusive). You may nominate an ANCO member (including yourself) to stand for election to the Board via e-mail to no later than November 15.
ASH News
On October 4, 1-2pm PDT, ASH is hosting the final of their new series titled the ASH Advocacy Webinar Series, Working with Advocacy Groups and Coalitions: How to Amplify Your Voice in Washington. ASH is committed to educating its members on how to become effective advocates for hematology research and practice. Registration is free and open to all interested. 
Advance registration for the 63rd ASH Annual Meeting & Exposition is well underway, and are counting down the days until we meet again! Don’t miss the premier event in hematology!
Catch up on what you missed and order webcasts from the 2021 ASH Meeting on Hematologic Malignancies and/or the 2021 ASH Consultative Hematology Course to access recordings of all the sessions. Learn from the experts about how their research and insights from their experience might improve your practice.
ASCO has created a temporary online job board to help connect oncology trainees with positions of employment, in lieu of the in-person networking received at the ASCO Annual Meeting. Between September 16 and October 15, 2021, trainees can view the list of available jobs, seek out more info, and apply. If you are recruiting trainees for open positions at your organization, please fill out the form or forward it to your hiring department.
Industry News
BeiGene announced their FDA accelerated approval to BRUKINSA® (zanubrutinib) capsules for the treatment of adult patients with relapsed or refractory Marginal Zone Lymphoma (MZL) who have received at least 1 anti–CD20-based regimen.
Incyte Corp. strives to provide assistance to physicians and patient education through their patient webinar programs. Please share this invitation with your patients and their caregivers who have been diagnosed with myeloproliferative neoplasms (MPN), including Polycythemia Vera, Essential thrombocythemia and Myelofibrosis. They will hear from Incyte Oncology Clinical Nurse Educators about MPNs. The last live webinar is tomorrow September 22. Thank you.
Seagen Inc. and Genmab A/S announced that the FDA has granted accelerated approval to TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is approved under the FDA’s Accelerated Approval Program based on tumor response and the durability of the response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.
Takeda Pharmaceuticals, Inc. announced their FDA approval of EXKIVITY™ (mobocertinib), the first oral therapy to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations in metastatic non-small cell lung cancer (NSCLC).1 EXKIVITY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.